Monoclonal gammopathy of undetermined significance natural history, complications and prognosis: Difference between revisions
Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Frequent complications of [[Monoclonal gammopathy of undetermined significance]] include fractures specially in [[lumbar]] vertebrae and [[Thromboembolic disease|thromboembolic]] phenomena. MGUS, is considered as a pre-malignant condition, and its transformation to [[multiple myeloma]]. However, as it mostly occurs in elderly, and its slow rate of progression, only a small proportion of people go on to develop a [[haematological malignancy]]. In patients with MGUS, although the actuarial risk of myeloma at 25 years of follow-up is 30%, the actual risk (when competing causes of death are taken into account) is only 11%. | |||
==Natural History== | ==Natural History== | ||
==Complications== | ==Complications== | ||
Line 16: | Line 18: | ||
==Prognosis== | ==Prognosis== | ||
* MGUS | * MGUS, is considered as a pre-malignant condition, and its transformation to multiple myeloma. However, as it mostly occurs in elderly, and its slow rate of progression, only a small proportion of people go on to develop a [[haematological malignancy]]. In patients with MGUS, although the actuarial risk of myeloma at 25 years of follow-up is 30%, the actual risk (when competing causes of death are taken into account) is only 11%.<ref>{{cite journal | author = Bladé J | title = Clinical practice. Monoclonal gammopathy of undetermined significance. | journal = N Engl J Med | volume = 355 | issue = 26 | pages = 2765-70 | year = 2006 | id =PMID 17192542 [http://content.nejm.org/cgi/content/short/355/26/2765 Abstract]}}</ref> | ||
* The annual risk of progressing to multiple myeloma is around 1–2% a year. | * The annual risk of progressing to multiple myeloma is around 1–2% a year. The prevalence of MGUS was 3.2% in people above 50, with a slight male predominance (4.0% vs. 2.7%). Prevalence increases with age. In people over 70 up to 5.3% had MGUS, while in the over-85 age group the prevalence was 7.5%. In the majority of cases (63.5%), the paraprotein level reported as <1 g/dl, while only a very small group reported levels over 2 g/dl.<ref name="Kyle">{{cite journal | author=Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd. | title=Prevalence of monoclonal gammopathy of undetermined significance | journal=N Engl J Med | year=2006 | month=28 December | volume=354| pages=1362-9 | id=PMID 16571879}}</ref> | ||
* In addition to multiple myeloma, MGUS may also progress to [[Waldenström's macroglobulinemia]], primary [[amyloidosis]], [[B-cell lymphoma]], or[[chronic lymphocytic leukemia]]. <font color="#777777">'</font> | * In addition to multiple myeloma, MGUS may also progress to [[Waldenström's macroglobulinemia]], primary [[amyloidosis]], [[B-cell lymphoma]], or[[chronic lymphocytic leukemia]]. <font color="#777777">'</font> |
Revision as of 16:27, 8 August 2018
Monoclonal gammopathy of undetermined significance Microchapters |
Differentiating Monoclonal gammopathy of undetermined significance from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Monoclonal gammopathy of undetermined significance natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance natural history, complications and prognosis |
on Monoclonal gammopathy of undetermined significance natural history, complications and prognosis |
Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Frequent complications of Monoclonal gammopathy of undetermined significance include fractures specially in lumbar vertebrae and thromboembolic phenomena. MGUS, is considered as a pre-malignant condition, and its transformation to multiple myeloma. However, as it mostly occurs in elderly, and its slow rate of progression, only a small proportion of people go on to develop a haematological malignancy. In patients with MGUS, although the actuarial risk of myeloma at 25 years of follow-up is 30%, the actual risk (when competing causes of death are taken into account) is only 11%.
Natural History
Complications
The following are frequent complications of Monoclonal gammopathy of undetermined significance
- Fractures specially in lumbar vertebrae[1][2][3][4]
- Thromboembolic phenomena[5][6]
- Hypercoaguable state[7][6]
- Development of secondary cancers eg. acute myeloid leukemia and myelodysplastic syndromes[8][9]
Prognosis
- MGUS, is considered as a pre-malignant condition, and its transformation to multiple myeloma. However, as it mostly occurs in elderly, and its slow rate of progression, only a small proportion of people go on to develop a haematological malignancy. In patients with MGUS, although the actuarial risk of myeloma at 25 years of follow-up is 30%, the actual risk (when competing causes of death are taken into account) is only 11%.[10]
- The annual risk of progressing to multiple myeloma is around 1–2% a year. The prevalence of MGUS was 3.2% in people above 50, with a slight male predominance (4.0% vs. 2.7%). Prevalence increases with age. In people over 70 up to 5.3% had MGUS, while in the over-85 age group the prevalence was 7.5%. In the majority of cases (63.5%), the paraprotein level reported as <1 g/dl, while only a very small group reported levels over 2 g/dl.[11]
- In addition to multiple myeloma, MGUS may also progress to Waldenström's macroglobulinemia, primary amyloidosis, B-cell lymphoma, orchronic lymphocytic leukemia. '
References
- ↑ Pepe J, Petrucci MT, Nofroni I, Fassino V, Diacinti D, Romagnoli E, Minisola S (September 2006). "Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance". Br. J. Haematol. 134 (5): 485–90. doi:10.1111/j.1365-2141.2006.06217.x. PMID 16848794.
- ↑ Melton LJ, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, Kyle RA (January 2004). "Fracture risk in monoclonal gammopathy of undetermined significance". J. Bone Miner. Res. 19 (1): 25–30. doi:10.1359/JBMR.0301212. PMID 14753733.
- ↑ Gregersen H, Jensen P, Gislum M, Jørgensen B, Sørensen HT, Nørgaard M (October 2006). "Fracture risk in patients with monoclonal gammopathy of undetermined significance". Br. J. Haematol. 135 (1): 62–7. doi:10.1111/j.1365-2141.2006.06269.x. PMID 16925792.
- ↑ Kristinsson SY, Tang M, Pfeiffer RM, Björkholm M, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O (October 2010). "Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study". Blood. 116 (15): 2651–5. doi:10.1182/blood-2010-04-282848. PMC 3324256. PMID 20610813.
- ↑ Sallah S, Husain A, Wan J, Vos P, Nguyen NP (October 2004). "The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance". Ann. Oncol. 15 (10): 1490–4. doi:10.1093/annonc/mdh385. PMID 15367409.
- ↑ 6.0 6.1 Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW (July 2007). "Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders". Clin Lymphoma Myeloma. 7 (7): 462–6. PMID 17875234.
- ↑ Kristinsson SY, Pfeiffer RM, Björkholm M, Goldin LR, Schulman S, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O (June 2010). "Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study". Blood. 115 (24): 4991–8. doi:10.1182/blood-2009-11-252072. PMC 2890150. PMID 20299513.
- ↑ Thomas A, Mailankody S, Korde N, Kristinsson SY, Turesson I, Landgren O (March 2012). "Second malignancies after multiple myeloma: from 1960s to 2010s". Blood. 119 (12): 2731–7. doi:10.1182/blood-2011-12-381426. PMC 3327452. PMID 22310913.
- ↑ Mailankody S, Pfeiffer RM, Kristinsson SY, Korde N, Bjorkholm M, Goldin LR, Turesson I, Landgren O (October 2011). "Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)". Blood. 118 (15): 4086–92. doi:10.1182/blood-2011-05-355743. PMC 3204729. PMID 21795746.
- ↑ Bladé J (2006). "Clinical practice. Monoclonal gammopathy of undetermined significance". N Engl J Med. 355 (26): 2765–70. PMID 17192542 Abstract.
- ↑ Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ 3rd. (2006). "Prevalence of monoclonal gammopathy of undetermined significance". N Engl J Med. 354: 1362–9. PMID 16571879. Unknown parameter
|month=
ignored (help)